Comparative Survival Outcomes of High-risk Prostate Cancer Treated with Radical Prostatectomy or Definitive Radiotherapy Regimens
Open Access
- 24 February 2021
- journal article
- research article
- Published by Elsevier BV in European Urology Open Science
- Vol. 26, 55-63
- https://doi.org/10.1016/j.euros.2021.01.011
Abstract
No abstract availableThis publication has 28 references indexed in Scilit:
- Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate CancerEndocrine, 2017
- EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative IntentEuropean Urology, 2017
- Ten- and 15-yr Prostate Cancer-specific Mortality in Patients with Nonmetastatic Locally Advanced or Aggressive Intermediate Prostate Cancer, Randomized to Lifelong Endocrine Treatment Alone or Combined with Radiotherapy: Final Results of The Scandinavian Prostate Cancer Group-7European Urology, 2016
- Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysisEuropean Urology, 2016
- Dose-Escalated Irradiation and Overall Survival in Men With Nonmetastatic Prostate CancerJAMA Oncology, 2015
- Utilization of Radiation Therapy in Norway After the Implementation of The National Cancer Plan—A National, Population-Based StudyEndocrine, 2014
- Radical Prostatectomy or Radiotherapy in High-Risk Prostate Cancer: A Systematic Review and MetaanalysisClinical Genitourinary Cancer, 2014
- Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomesBMJ, 2014
- Long-Term Failure Patterns and Survival in a Randomized Dose-Escalation Trial for Prostate Cancer. Who Dies of Disease?Endocrine, 2011
- External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised studyThe Lancet Oncology, 2010